CKPT
Income statement / Annual
Last year (2023), Checkpoint Therapeutics, Inc.'s total revenue was $103,000.00,
a decrease of 46.35% from the previous year.
In 2023, Checkpoint Therapeutics, Inc.'s net income was -$51.85 M.
See Checkpoint Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$103,000.00 |
$192,000.00 |
$268,000.00 |
$1.07 M |
$1.71 M |
$3.51 M |
$1.73 M |
$2.57 M |
$590,000.00 |
| Cost of Revenue |
$43.57 M
|
$49.83 M
|
$48.45 M
|
$16.35 M
|
$19.33 M
|
$33.65 M
|
$19.08 M
|
$20.27 M
|
$11.32 M
|
| Gross Profit |
-$43.46 M
|
-$49.63 M
|
-$48.19 M
|
-$15.28 M
|
-$17.62 M
|
-$30.15 M
|
-$17.36 M
|
-$17.70 M
|
-$10.73 M
|
| Gross Profit Ratio |
-421.97
|
-258.51
|
-179.8
|
-14.3
|
-10.31
|
-8.6
|
-10.06
|
-6.89
|
-18.19
|
| Research and Development Expenses |
$43.57 M
|
$49.83 M
|
$48.45 M
|
$16.35 M
|
$19.33 M
|
$33.65 M
|
$19.08 M
|
$20.27 M
|
$11.32 M
|
| General & Administrative Expenses |
$8.69 M
|
$8.70 M
|
$8.54 M
|
$7.92 M
|
$7.23 M
|
$6.59 M
|
$5.42 M
|
$4.47 M
|
$2.49 M
|
| Selling & Marketing Expenses |
$0.00
|
$400,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.69 M
|
$8.70 M
|
$8.54 M
|
$7.92 M
|
$7.23 M
|
$6.59 M
|
$5.42 M
|
$4.47 M
|
$2.49 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$225,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$52.25 M
|
$58.53 M
|
$56.99 M
|
$24.27 M
|
$26.56 M
|
$40.25 M
|
$24.50 M
|
$24.73 M
|
$13.81 M
|
| Cost And Expenses |
$52.25 M
|
$58.53 M
|
$56.99 M
|
$24.27 M
|
$26.56 M
|
$40.25 M
|
$24.50 M
|
$24.73 M
|
$13.81 M
|
| Interest Income |
$84,000.00
|
$160,000.00
|
$53,000.00
|
$120,000.00
|
$136,000.00
|
$148,000.00
|
$98,000.00
|
$47,000.00
|
$2,000.00
|
| Interest Expense |
$0.00
|
$4.29 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$344,000.00
|
$235,000.00
|
| Depreciation & Amortization |
$0.00
|
$4.45 M
|
$236,558.00
|
$206,297.00
|
$171,860.00
|
$36.74 M
|
$22.78 M
|
$22.16 M
|
$2,000.00
|
| EBITDA |
-$52.15 M |
-$58.33 M |
-$56.72 M |
-$23.20 M |
-$24.85 M |
-$36.74 M |
-$22.68 M |
-$22.12 M |
-$13.22 M |
| EBITDA Ratio |
-506.29
|
-280.64
|
-211.65
|
-21.7
|
-14.55
|
-10.48
|
-13.15
|
-8.61
|
-22.41
|
| Operating Income Ratio |
-506.29
|
-303.82
|
-211.65
|
-21.7
|
-14.55
|
-10.48
|
-13.2
|
-8.62
|
-22.41
|
| Total Other Income/Expenses Net |
$301,000.00
|
-$4.29 M
|
$53,000.00
|
$120,000.00
|
$136,000.00
|
$373,000.00
|
$98,000.00
|
-$297,000.00
|
-$671,000.00
|
| Income Before Tax |
-$51.85 M
|
-$62.62 M
|
-$56.67 M
|
-$23.08 M
|
-$24.71 M
|
-$36.37 M
|
-$22.68 M
|
-$22.46 M
|
-$13.89 M
|
| Income Before Tax Ratio |
-503.37
|
-326.17
|
-211.46
|
-21.59
|
-14.47
|
-10.37
|
-13.15
|
-8.74
|
-23.55
|
| Income Tax Expense |
$0.00
|
$4.29 M
|
-$53,000.00
|
-$120,000.00
|
-$136,000.00
|
-$521,000.00
|
-$22.68 M
|
-$22.12 M
|
$233,000.00
|
| Net Income |
-$51.85 M
|
-$66.92 M
|
-$56.62 M
|
-$22.96 M
|
-$24.58 M
|
-$36.37 M
|
-$22.68 M
|
-$22.46 M
|
-$13.89 M
|
| Net Income Ratio |
-503.37
|
-348.52
|
-211.26
|
-21.48
|
-14.39
|
-10.37
|
-13.15
|
-8.74
|
-23.55
|
| EPS |
-2.77 |
-7.57 |
-7.45 |
-4.11 |
-6.96 |
-12.74 |
-10.03 |
-10.43 |
-5.69 |
| EPS Diluted |
-2.77 |
-7.57 |
-7.45 |
-4.11 |
-6.96 |
-12.74 |
-10.03 |
-10.43 |
-5.69 |
| Weighted Average Shares Out |
$18.74 M
|
$8.84 M
|
$7.60 M
|
$5.58 M
|
$3.53 M
|
$2.86 M
|
$2.26 M
|
$2.15 M
|
$2.44 M
|
| Weighted Average Shares Out Diluted |
$18.74 M
|
$8.84 M
|
$7.60 M
|
$5.58 M
|
$3.53 M
|
$2.86 M
|
$2.26 M
|
$2.15 M
|
$2.44 M
|
| Link |
|
|
|
|
|
|
|
|
|
